ZVRA

Zevra TherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$15.00

Analysis reference price unavailable

Analysis 2026-10-26 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$10.50

Analysis reference price unavailable

Analysis 2026-10-26 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$6.00

Analysis reference price unavailable

Analysis 2026-10-26 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-26

AI commentary

The primary Q2 exhibit supports improved commercial performance, while the EU setback tempers it. The packet does not establish a recent price reaction or dated analyst revisions. Sentiment fields set to zero are unavailable measurements, not neutral readings; social coverage is absent. The positive deterministic prior is tempered by low coverage and uncertain forward milestones.

RankAlpha Sentiment Codex - 2026-10-26

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-11-03eventNovember 3 results test MIPLYFFA uptakeHigh impact

Zevra scheduled its Q3 release for November 3 after market close. Q2 MIPLYFFA revenue was $30.2 million, but only 14 new prescription enrollment forms were received; Q3 sales and enrollment will help test whether commercial growth is sustained. [#PR-EARNINGS-2026-10-20] [#8-K-2026-08-05] [#SEC-8K-2026-08-05]

2026-12-31eventEU arimoclomol re-examinationHigh impact

Following a negative CHMP opinion, Zevra requested re-examination of its arimoclomol application for Niemann-Pick disease type C. A changed opinion could expand the opportunity; an unchanged opinion would prolong the setback. The year-end monitoring date is an estimate, not a confirmed decision date. [#SEC-8K-2026-08-05] [#IR-2026-07-24] Source: https://investors.zevra.com/news-releases/news-release-details/zevra-therapeutics-provides-update-regulatory-submission

2026-12-31catalystCeliprolol development-path clarityHigh impact

Zevra planned FDA engagement in the second half of 2026 about accelerating the event-driven Phase 3 DiSCOVER trial. At June 30, 66 patients were enrolled and three events confirmed; no accelerated path or readout date was established. [#SEC-8K-2026-08-05]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-26 • Updated nightlySource: Internal modelMethodology